Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Fragile X syndrome
Paediatrics and child health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
Overview
Recognise Fragile X syndrome in children and families, request mechanism-appropriate FMR1 testing, distinguish full mutation from premutation implications, assess associated health needs and provide accurate reproductive counselling.
Fragile X syndrome is a common inherited cause of intellectual disability and a recognised genomic cause of autism. It usually arises when a CGG repeat in the 5-prime untranslated region of FMR1 expands into the full-mutation range and becomes abnormally methylated, reducing production of FMRP. The laboratory report should state repeat category and, where assessed, methylation or mosaicism. A clinical appearance is insufficient because young children may lack the later long face, prominent ears or macro-orchidism and girls can have subtle or isolated learning, anxiety or social difficulties.
Presentation is developmentally broad. Early clues include delayed speech, hypotonia, poor coordination, sensory sensitivity, gaze avoidance, repetitive behaviour, hyperactivity, impulsivity and marked anxiety during transitions. Cognitive ability can range widely, especially in females. The phenotype may include joint hypermobility, flat feet, recurrent otitis media, strabismus, seizures and sleep problems. Record strengths and communication style as carefully as impairment. A sudden change still requires a search for pain, hearing loss, epilepsy, sleep disruption, bullying or another illness.
Testing must match the molecular mechanism and the current NHS pathway. Technological advances allow validated whole-genome sequencing analysis to identify the FMR1 expansion reliably, so suspected Fragile X syndrome is now investigated through broader genomic testing that can also assess other causes of syndromic intellectual disability rather than an isolated short-tandem-repeat request. Chromosomal microarray does not exclude the expansion. Full-mutation, premutation, intermediate and typical repeat categories have different meanings; preserve the laboratory wording and seek genetics advice for boundary, mosaic or methylation complexity.
Inheritance counselling separates the child from the wider family. A full-mutation male passes his altered X chromosome to all daughters and no sons, but his daughters generally inherit a premutation because large full mutations contract in sperm. A woman with a premutation can transmit an allele that expands to a full mutation; expansion probability rises with repeat length and is modified by AGG interruptions. Women with a full mutation have a one-in-two chance of passing the altered X chromosome in each pregnancy, while clinical expression in daughters is variable because of X-inactivation.
Premutation status has personal health implications. Some female carriers develop Fragile-X-associated primary ovarian insufficiency, and some older carriers, particularly men, develop a progressive tremor-ataxia syndrome. Anxiety, mood or other neuropsychiatric symptoms may also require assessment, but not every carrier becomes symptomatic. Relatives should receive individual counselling and appropriate referrals rather than having predictive diagnoses entered from family relationship alone. Testing children solely for adult-onset premutation complications needs careful consideration of present benefit and future autonomy.
There is no medicine that corrects the underlying FMR1 silencing in routine NHS care. Support begins with detailed developmental and functional assessment. Speech and language therapy can develop expressive, receptive and augmentative communication. Occupational and physiotherapy address sensory regulation, motor coordination and daily skills. School plans should reduce unpredictable overload, teach in small structured steps and provide positive behavioural support. NICE pathways for autism, ADHD, sleep or challenging behaviour apply when those clinical diagnoses or needs are present, with adjustments for intellectual and communication disability.
Follow-up should be anticipatory but proportionate. Check hearing and vision because sensory impairment compounds learning. Characterise any episodes before prescribing antiseizure treatment. Review growth, feeding, gastrointestinal symptoms, sleep, anxiety, attention, behaviour, mobility and family stress. Cardiovascular examination is reasonable, with specialist assessment for murmur, symptoms or known connective-tissue findings rather than indiscriminate imaging. At transition, transfer the molecular report, communication plan, reasonable adjustments, medicines, capacity supports and family genetics contact.
Key points
Consider Fragile X syndrome in unexplained developmental or intellectual disability, autism, prominent anxiety or hyperarousal, especially with suggestive male relatives or premature ovarian insufficiency in the family.
Physical features such as long face, large ears, joint laxity and post-pubertal macro-orchidism are variable and often subtle in young children; they cannot confirm or exclude diagnosis.
Use the current NHS broader genomic pathway, now including whole-genome detection of FMR1 expansion; chromosomal microarray remains unable to exclude Fragile X syndrome.
Distinguish a full mutation causing Fragile X syndrome from a premutation, which has different reproductive and adult health implications and is not simply a mild full mutation.
Assess hearing, vision, growth, sleep, seizures, attention, anxiety, autism, communication, motor skills and adaptive function rather than using a single global developmental label.
Management is multidisciplinary and goal-based: communication support, predictable environment, education planning, behavioural formulation, therapy and treatment of specific coexisting conditions.
Offer clinical genetics review to explain expansion risk through maternal transmission, testing options for relatives and reproductive choices without directing family decisions.
Use accessible disclosure as the child matures, protect privacy and avoid deterministic predictions about ability or future independence from repeat size alone.
Aetiology
01
FMR1 full mutation
Expansion beyond the full-mutation threshold, usually with abnormal methylation, silences FMR1 and reduces fragile X messenger ribonucleoprotein needed for neuronal development.
02
X-linked inheritance
The altered FMR1 allele lies on the X chromosome; transmission, expansion and clinical expression differ by parental sex, repeat size and methylation.
03
Premutation instability
A maternal premutation, approximately 55 to 200 CGG repeats depending on laboratory thresholds, can expand to a full mutation in one generation; repeat length and AGG interruptions modify probability.
Pathophysiology
1
Synaptic signalling dysregulation
Loss of FMRP alters translation and maturation at neuronal synapses, affecting learning, sensory processing, attention, anxiety and adaptive behaviour.
2
Sex-dependent expression
Males with a full mutation are often more affected, while X-inactivation creates wide cognitive and behavioural variability among heterozygous females.
3
Connective tissue effects
Altered connective-tissue phenotype contributes to joint laxity, flat feet, soft skin, prominent ears and later macro-orchidism without defining diagnosis.
4
Premutation RNA toxicity
Premutation alleles usually retain FMR1 expression but excess abnormal RNA contributes to adult ovarian insufficiency and tremor-ataxia syndromes in some carriers.
Clinical features and red flags
Developmental presentation
Language delay, intellectual disability, autistic features, sensory hyperarousal and attention difficulty form the common childhood presentation.
Physical clues
Long narrow face, prominent ears, joint laxity, flat feet and post-pubertal macro-orchidism support suspicion but vary with age and sex.
Family pattern
More severely affected males connected through maternal relatives, unexplained learning difficulty or ovarian insufficiency can reveal X-linked FMR1 risk.
Female phenotype
Girls may have learning, executive, social, anxiety or mathematical difficulty despite fewer classic physical findings and comparatively preserved general ability.
Premutation clue
Early ovarian insufficiency or later intention tremor, gait ataxia and cognitive change in relatives can indicate carrier-associated disease.
Red flags requiring action
Developmental regression, new focal neurological signs, prolonged seizures or acute loss of skills requires urgent assessment for another neurological disorder rather than attribution to Fragile X syndrome.
A child with severe agitation, reduced sleep and abrupt behavioural change needs assessment for pain, illness, medication effects, abuse or mental-health crisis before behaviour is labelled syndromic.
Investigations
01Whole-genome analysis including FMR1 expansionFirst step
Why
Detect the CGG expansion while evaluating other genomic causes of syndromic intellectual disability.
Interpretation and limitations
Use the current NHS indication and laboratory thresholds; repeat category, mosaicism and methylation context still need specialist explanation.
02FMR1 methylation analysis
Why
Assess epigenetic silencing and clarify full-mutation or mosaic findings.
Interpretation and limitations
Methylation contributes to expression but cannot predict an individual's cognitive outcome precisely.
03Developmental and adaptive assessment
Why
Define cognition, language, motor, social and daily-living needs for support.
Interpretation and limitations
A profile of strengths and needs guides intervention more usefully than the molecular diagnosis alone.
04Hearing and vision testing
Why
Identify sensory impairment that may mimic or worsen communication difficulty.
Interpretation and limitations
Treatable conductive hearing loss or refractive error can materially improve learning and behaviour.
05Symptom-directed EEG or cardiac assessment
Why
Differential diagnosis
01
Non-syndromic autism
Social communication difference, sensory sensitivity and repetitive behaviour are common but do not identify an FMR1 mechanism without genomic testing.
02
Other genomic syndrome
Copy-number disorders, Rett-spectrum disease and numerous monogenic conditions can cause developmental delay with behavioural or physical overlap.
03
Sotos or overgrowth syndrome
Long face, large ears, developmental difference and increased growth can resemble aspects of Fragile X but have different growth and molecular patterns.
04
ADHD or anxiety disorder
Attention, hyperarousal and avoidance may be clinically important diagnoses while also forming part of the broader neurodevelopmental phenotype.
Management
01SuspectRecognise a genomic neurodevelopmental patternFirst stepDevelopmental differences coexist with Fragile-X-compatible behaviour, features or family history.+
1Document developmental domains, examination, growth, sensory findings and a three-generation pedigree.
2Refer through the eligible NHS broader genomic pathway and ensure FMR1 expansion analysis is included.
3Continue hearing, vision, developmental and safeguarding assessment while the molecular result is pending.
02SupportTranslate diagnosis into functionFragile X syndrome is confirmed or the child's needs are already evident.+
1Create communication, sensory, education and positive-behaviour supports around assessed strengths and triggers.
2Diagnose and manage epilepsy, ADHD, anxiety, autism, sleep or pain through appropriate adjusted pathways.
Complications
01
Learning and adaptive disability
Cognitive, language, executive and daily-living difficulties vary substantially and can restrict participation when communication support is absent.
02
Anxiety and behavioural distress
Hyperarousal, sensory overload, ADHD, autistic features, sleep difficulty and self-injury may emerge from interacting neurobiology and environment.
03
Seizures
Epilepsy occurs in a minority and needs seizure classification and standard evidence-based treatment rather than syndrome-specific assumptions.
04
Connective tissue morbidity
Joint laxity, flat feet, recurrent otitis, strabismus and occasional mitral valve or aortic-root findings can require targeted care.
05
Carrier-associated adult disease
Premutation relatives may face primary ovarian insufficiency or later tremor-ataxia, creating health implications beyond reproductive recurrence.
Monitoring and follow-up
Review communication, adaptive skills, learning and participation with school and therapy teams using meaningful functional outcomes.
Check hearing, vision, dental health, sleep, seizures, growth, feeding, bowel symptoms, mobility and pain at clinically appropriate intervals.
Track anxiety, attention, sensory overload, self-injury and family stress, reassessing precipitants before changing behavioural treatment.
Confirm whether at-risk adult relatives received an appropriate genetics route for reproductive and premutation-associated health questions.
At transition, review consent, privacy, capacity support and the young person's own understanding rather than directing all information through parents.
Special situations
Use the current pathway
Validated whole-genome analysis can now diagnose FMR1 expansion, while a normal chromosomal microarray still cannot exclude Fragile X syndrome.
Premutation is clinically distinct
Carrier alleles have reproductive instability and selected adult health associations without being merely a less severe childhood full mutation.
Girls can be missed
Variable X-inactivation may produce specific learning, anxiety or social difficulty without the more recognised male phenotype.
Behaviour communicates context
Noise, unpredictability, pain, communication failure and anxiety can drive distress and should be formulated before restrictive intervention.
Repeat size is not destiny
Methylation, mosaicism, X-inactivation, environment and support prevent precise prediction of individual ability from a laboratory number.
Common pitfalls
01
Relying on facial appearance to confirm or exclude Fragile X syndrome.
02
Requesting an obsolete isolated repeat test without checking the current NHS genomic pathway.
03
Describing a premutation as a mildly affected full mutation.
04
Predicting cognitive outcome directly from repeat length alone.
05
Attributing abrupt regression or distress to baseline behaviour without medical assessment.
06
Giving family recurrence advice without reviewing the transmitting parent's result and sex.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Paediatrics and child healthOriginal SBA
Mechanism-matched Fragile X test
A boy has developmental delay, autistic features, joint laxity and maternal male relatives with intellectual disability. Which investigation best matches the current NHS genomic pathway?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Syncope, exertional chest pain or sustained palpitations warrants ordinary emergency cardiovascular assessment even when mitral valve prolapse has previously been documented.
A female premutation carrier with neurological symptoms or ovarian dysfunction, or an older male carrier with tremor and ataxia, needs their own specialist assessment rather than care only through the child.
Evaluate suspected seizures, syncope, murmur or cardiovascular symptoms.
Interpretation and limitations
Testing follows the clinical problem; the Fragile X label alone does not establish epilepsy or cardiac disease.
3
Review family wellbeing, respite, benefits, school planning and accessible information at meaningful intervals.
03CounselMap full mutation and premutation implicationsThe FMR1 result may affect parents, siblings or extended relatives.+
1Explain repeat category, sex-linked transmission, expansion and limitations without predicting severity deterministically.
2Offer clinical genetics routes for at-risk relatives and carrier-associated adult health assessment.
3Discuss reproductive testing and conception options neutrally according to the person's own values and timing.
04TransitionPreserve genomic and support continuityThe young person moves toward adult healthcare, education or social services.+
1Give the young person an accessible explanation and private opportunities to ask about inheritance.
2Transfer the original molecular report, communication profile, reasonable adjustments and active health plan.
3Identify adult primary-care, neurology, mental-health, learning-disability and genetics ownership as individually required.